Frailty in HIV linked to inflammation, bone health, T-cell exhaustion - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Frailty in HIV linked to inflammation, bone health, T-cell exhaustion

Osteoprotegerin was the soluble marker most strongly linked to T-cell phenotypes among participants with frailty.

  • By

  • Olivia Anderson

  • September 8, 2026

  • 3 min

Share

Clinical Scorecard: Frailty in HIV linked to inflammation, bone health, T-cell exhaustion

At a Glance

CategoryDetail
ConditionFrailty in HIV
Key MechanismsInflammatory proteins, bone health markers, T-cell exhaustion
Target PopulationIndividuals with HIV
Care SettingHIV Infection, Aging, and Immune Function Long-Term Observational Study (HAILO)

Key Highlights

  • Frailty defined using modified Fried criteria.
  • 19 of 75 plasma markers significantly associated with frailty.
  • Lower naïve CD4 and CD8 T cells in frail individuals.
  • Osteoprotegerin (OPG) linked to T-cell phenotypes and bone health.
  • Study does not establish causation due to cross-sectional design.

Guideline-Based Recommendations

Diagnosis

  • Frailty assessed using modified Fried criteria.

Management

  • Monitor inflammatory markers and T-cell phenotypes.

Monitoring & Follow-up

  • Evaluate bone health and immune function in individuals with HIV.

Risks

  • Potential for increased frailty linked to inflammation and immune activation.

Patient & Prescribing Data

120 participants with HIV, half meeting frailty criteria.

OPG may inhibit osteoclast formation and prevent bone resorption.

Clinical Best Practices

  • Assess frailty in HIV patients using established criteria.
  • Consider inflammatory and bone health markers in management.

Related Resources & Content

Original Source(s)

Frailty in HIV linked to inflammation, bone health, T-cell exhaustion

  • by Olivia Anderson

  • September 8, 2026

Related Content

CDC Ebola update: Outbreak outpaces 2018 surge

More than 120 CDC personnel have been deployed to affected countries as the agency responds to the world's second-largest Ebola outbreak on record.

PrEP surfing common among MSM

Reliance on partners’ PrEP use was more common among younger men and those who had used PrEP in the previous 6 months.

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.